M9466 + Tuvusertib for Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.
Will I have to stop taking my current medications?
The trial requires a washout period (time without taking certain medications) of 4 weeks for most prior treatments before starting the study drugs. If you are on ongoing ADT (androgen deprivation therapy) for prostate cancer, you must continue it throughout the study.
Eligibility Criteria
This trial is for individuals with advanced solid tumors. Participants will receive treatment until their disease progresses, they pass away, decide to leave the study, or when the study ends. They'll visit the clinic weekly at first and then every three weeks.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive M9466 alone or in combination with tuvusertib or an ARPi. Treatment continues until disease progression, death, discontinuation, or End of Study.
End of Treatment
An End of Treatment Visit is conducted to assess participant status at the conclusion of the treatment phase.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- M9466 (Monoclonal Antibodies)
- Tuvusertib (Other)